A recent Twitter conversation between a blogging colleague of mine and a German advocate of precision medicine propelled this post: What is the real benefit of biosimilars? Does biosimilar development detract from efforts to produce innovative medicines? Is the main societal benefit biosimilar cost savings? Biosimilar Development Is Separate From Innovation Development The main reason … Continue reading Let’s not Knock Innovation, but Biosimilars Exist for the Sake of Competition
Tag: cost savings
Trastuzumab Dosing May Be Given in Half the Time: Will Costs/Revenues Be Cut as Well?
An upcoming presentation at the annual American Society of Clinical Oncology (ASCO) meeting promises equal efficacy and much improved safety for patients with early-stage breast cancer receiving Herceptin®. This change in trastuzumab dosing from a 12-month to a 6-month regimen will have ramifications for patients, health systems, and manufacturers. A number of biosimilar drug makers … Continue reading Trastuzumab Dosing May Be Given in Half the Time: Will Costs/Revenues Be Cut as Well?
Payers’ Expectations for Biosimilars Reflect a Conflicted Environment
Hopeful but not enthusiastic. Preparing but not anticipating. Those are the impression one gets when speaking to medical directors and pharmacy directors of health plans, insurers, and pharmacy benefit managers about biosimilars today. Although savings associated with biosimilar use have been limited so far, one recently released survey of these payers revealed expectations that seem … Continue reading Payers’ Expectations for Biosimilars Reflect a Conflicted Environment
Evidence to Support Zarxio Use Presented at AMCP
Researchers studied the effect of a step edit, requiring the use of either Zarxio or Granix first, and its effect on utilization trends and cost savings among 2.7 million covered lives.